Wednesday, July 8, 2026

Patent intelligence · US

US 12383636

Marking precursor with squaric acid coupling

granted A61KA61K47/54A61K51/0402A61K51/0446
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 19
Applicant portfolio 3
Patent details — US 12383636
Jurisdiction
US
Status
granted
Grant date
Aug 12, 2025
Expiration
Aug 7, 2045
Claims
6
CPC classes
A61K, A61K47/54, A61K51/0402, A61K51/0446
View on Google Patents ↗

Quick answer

US 12383636 (Marking precursor with squaric acid coupling) is held by Telix Pharmaceuticals Limited. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
6
CPC classes
A61K, A61K47/54, A61K51/0402, A61K51/0446, A61K51/0455, A61K51/0478

More from Telix Pharmaceuticals Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12329829

    Kit for radiolabelling with 68GA comprising a metal inhibitor

    Telix Innovations S.A. · Expires Jun 12, 2045

    granted
  2. US 12121828

    Systems and methods of isolation of gallium-68

    Telix ARTMS Inc. · Expires Oct 17, 2044

    granted

Frequently asked questions

What is US patent 12383636?

US 12383636 (Marking precursor with squaric acid coupling) is held by Telix Pharmaceuticals Limited. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12383636?

Telix Pharmaceuticals Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.

When does US 12383636 expire?

Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.